In parallel, cellular therapies like CAR-T cells targeting PSMA or PSCA hold promise, although their potential is currently hindered by T cell exhaustion and “on-target, off-tumor” toxicities; novel approaches that engineer T cells with dominant-negative PD-1 or IL-12 expression are being explored to enhance durability [156]. This evidence concerns the gene FOLH1 and neoplasm.